Bayer's profit rises 53% and reaches 1 billion euros

The German pharmaceutical Bayer's net profit rose 53.5% in the first quarter, compared to the previous year, according to information released today by the company. The final line of the balance sheet stood at 1.05 billion euros or 1.27 euro per share.
The company's sales were higher, on the same basis, in all regions in which it is present. In the balance sheet, the high of 13.9% in products shipped to North America, especially the United States. The billing in this block was of 2.57 billion euros.
In total, Bayer's net revenue reached 10.06 billion euros, growing 6.8% compared to the same period in 2011. The main drivers of this expansion were the areas of pharmaceuticals, which sold 4 percent more, or 2.52 billion euros, and the segment of agricultural science, with a turnover of 2.61 billion euros, 15.6%.
The Group's numbers still show that the Ebitda, or earnings before interest, taxes, depreciation and amortization, rose 27.4% in comparison with the same period in 2011, to 2.38 billion euros. This, plus the non-operating gains, as in financial investments, to 111 million euros, contributed to the final profit.